Cardiac Amyloidosis Discovery Trial

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cardiac Amyloidosis
Interventions
DEVICE

Cardiac amyloidosis deep learning model

This is a deep learning algorithm which intakes a patient's age, sex, clinical factors known to be related to amyloidosis and their ECG and echocardiogram results and determines their estimated risk for having cardiac amyloidosis.

Trial Locations (1)

10032

RECRUITING

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

American Heart Association

OTHER

collaborator

Eidos Therapeutics, a BridgeBio company

INDUSTRY

lead

Pierre Elias

OTHER